01548.HK
Genscript Biotech Corporation
HKSE · Healthcare · Biotechnology · CN
HKD 31.46
−13.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 959.5M | 594.5M | 560.5M | 625.7M |
| Cost of Revenue | 774.1M | 406.3M | 322.4M | 289.9M | 321.6M |
| Gross Profit | 898.0M | 553.2M | 272.1M | 270.6M | 304.1M |
| Operating Expenses | |||||
| R&D Expense | 139.5M | 71.2M | 53.8M | 52.7M | 390.1M |
| SG&A Expense | 453.6M | 226.7M | 209.1M | 191.7M | 352.1M |
| General & Admin Expense | 190.2M | 128.6M | 114.4M | 106.8M | 182.5M |
| Selling & Marketing Expense | 144.6M | 99.5M | 88.1M | 80.1M | 168.3M |
| Other Expenses | — | — | — | — | (138.0K) |
| Total Operating Expenses | 593.0M | 298.0M | 262.8M | 244.4M | 742.1M |
| Cost and Expenses | 1.4B | 704.3M | 585.2M | 534.3M | 1.1B |
| Operating Income (EBIT) | 305.0M | 255.2M | 9.3M | 26.2M | (438.1M) |
| Non-Operating | |||||
| Interest Income | 53.7M | 26.1M | 28.9M | 73.2M | 13.2M |
| Interest Expense | 22.5M | 17.3M | 8.0M | 27.5M | 13.3M |
| Net Interest Income | 31.2M | 8.8M | 20.9M | 45.7M | (51.0K) |
| Other Non-Op Income/Expense | (937.5M) | (725.8M) | (180.1M) | 142.7M | 6.3M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (632.5M) | (470.5M) | (170.8M) | 168.9M | (431.7M) |
| Income Tax Expense | 78.6M | 61.9M | 3.0M | 6.0M | (3.7M) |
| Bottom Line | |||||
| Net Income | 2.5B | (532.8M) | 3.0B | (95.5M) | (226.9M) |
| Earnings from Cont. Ops | (697.5M) | (532.4M) | (173.8M) | 162.9M | (428.0M) |
| Earnings from Discont. Ops | 3.1B | — | 3.0B | (518.0M) | — |
| Bottom Line Net Income | (631.8M) | (532.8M) | (67.2M) | 422.5M | (226.9M) |
| Per Share | |||||
| Basic EPS | (HK$0.30) | (HK$0.25) | (HK$0.03) | HK$0.20 | (HK$0.11) |
| Diluted EPS | (HK$0.30) | (HK$0.25) | (HK$0.03) | HK$0.20 | (HK$0.11) |
| Revenue Per Share | HK$0.77 | HK$0.44 | HK$0.27 | HK$0.27 | HK$0.30 |
| Shares | |||||
| Basic Shares Outstanding | 2.2B | 2.2B | 2.2B | 2.1B | 2.1B |
| Diluted Shares Outstanding | 2.2B | 2.2B | 2.2B | 2.1B | 2.1B |
| Profitability Metrics | |||||
| EBITDA | 435.6M | 317.6M | 70.0M | 83.5M | (389.0M) |
| D&A | 130.6M | 62.4M | 60.8M | 57.3M | 49.1M |
| EBIT | 305.0M | 255.2M | 9.3M | 26.2M | (438.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026